EBI3 anticorps (AA 150-200)

N° du produit ABIN6991042

Cet anticorps Lapin Polyclonal détecte spécifiquement EBI3 dans WB, ELISA, IHC (p) et IF. Il présente une réactivité envers Humain, Souris et Rat.

Aperçu rapide pour EBI3 anticorps (AA 150-200) (ABIN6991042)

Antigène: EBI3 (IL-27b) (Interleukin-27 subunit beta (IL-27b))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp EBI3 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)

Détail du produit anti-EBI3 anticorps

Épitope: AA 150-200

Purification: EBI3 Antibody is affinity chromatography purified via peptide column.

Immunogène: Anti-EBI-3 antibody was raised against a peptide corresponding to 16 amino acids near the center of mature human EBI-3. The immunogen is located within amino acids 150 - 200 of EBI3.

Isotype: IgG

Information d'application

Indications d'application: WB: 0.5 - 2 μ,g/mL, IF: 20 μ,g/mL , IHC: 2.5 μ,g/mL,.

Antibody validated: Western Blot in human and rat samples, Immunofluorescence and Immunohistochemistry in human samples. All other applications and species not yet tested.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: EBI3 Antibody is supplied in PBS containing 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,4 °C

Stockage commentaire: EBI3 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Détails sur EBI3

Antigène: EBI3 (IL-27b) (Interleukin-27 subunit beta (IL-27b))

Autre désignation: EBI3

Sujet: EBI3 Antibody: EBI3 is a subunit in two distinct heterodimeric cytokines: interleukin-27 (IL-27) and IL-35. Like interleukin-23 (IL-23), IL-27 is a recently discovered member of the IL-6/IL-12 family of proinflammatory and immunoregulatory cytokines. It exists as a heterodimer composed of the p40-related protein EBI3 and an IL-12 p35-related protein termed p28. IL-27 is produced after activation by antigen-presenting cells and induces proliferation of naive but not memory CD4+ T-cells. It acts by binding to its receptor WSX-1 (also known as TCCR) and gp130 which results in the activation of a Jak/STAT signaling cascade, suggesting the IL-27 is involved in the regulation of immune processes. It has been suggested that IL-27 can also be used as a therapeutic agent against cancer as it can also induce tumor-specific anti-tumor activity mediated through CD8+ T-cells, IFN-gamma, and T-bet. IL-35 is composed of EBI3 and the p35 subunit of IL-12 and has been reported to have therapeutic effects against collagen-induced arthritis by expanding the population of regulatory T cells and suppressing Th17 cells. At least two isoform of EBI3 are known to exist.

Poids moléculaire: Predicted: 25kD

Observed: 30 kD (25kD + 2 N-Glycosylations) kDa

ID gène: 10148

NCBI Accession: NP_005746

UniProt: Q14213